Related Experiment Video
Updated: Jul 11, 2026
Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus
Published on: May 7, 2012
B-lymphocytes as targets for therapy in chronic cold agglutinin disease
Sigbjørn Berentsen1, Elling Ulvestad, Geir E Tjønnfjord
1Department of Medicine, Haugesund Hospital, Haugesund, Norway. s.beren@online.no
Insights
Primary chronic cold agglutinin disease (CAD) is an autoimmune disorder. New combination therapy with rituximab and fludarabine shows promising preliminary results for improving treatment response rates and duration in CAD patients.
Area of Science:
- Hematology
- Immunology
- Autoimmune Diseases
Background:
- Primary chronic cold agglutinin disease (CAD) is an autoimmune hemolytic anemia caused by cold agglutinins targeting red blood cells.
- Current treatments like corticosteroids and alkylating agents offer disappointing results.
- CAD pathogenesis involves monoclonal B lymphocytes expressing CD20 and kappa light chains, identified via flow cytometry and immunohistochemistry.
Purpose of the Study:
- To evaluate the efficacy and duration of response of a combination therapy for primary chronic cold agglutinin disease.
- To investigate novel therapeutic strategies beyond single-agent rituximab for CAD.
Main Methods:
- Phase 2 study evaluating combination therapy with rituximab and fludarabine.
- Assessment of response rates and duration of response in patients with primary CAD.
Main Results:
- Preliminary results of the rituximab and fludarabine combination therapy are encouraging.
- Rituximab monotherapy shows partial response rates of approximately 50% with a median response duration of 11 months.
- Inconstant efficacy of rituximab may be linked to complement C3/C4 depletion and Fc-gamma-RIIIa receptor polymorphism.
Conclusions:
- Combination therapy with rituximab and fludarabine demonstrates potential for improved outcomes in primary CAD.
- Further studies are necessary to confirm the efficacy and durability of this combination therapy.
- Understanding factors like complement levels and Fc receptor polymorphism may guide future treatment strategies.
Abstract:
Primary chronic cold agglutinin disease (CAD) is an autoimmune hemolytic anemia induced by cold reactive autoantibodies (cold agglutinins) against erythrocyte surface antigens. Corticosteroids or alkylating agents have been used in the treatment of CAD, but the results have been disappointing. The cold agglutinins in CAD patients are monoclonal immunoglobulins, usually of the IgMkappa type encoded by the V(H)4-34 gene segment. Flowcytometric assessment of lymphocytes from bone marrow aspirates and immunohistochemical assessment of biopsy samples have revealed a monoclonal CD20(+) kappa(+) B lymphocyte population in 90% of the patients. These pathogenetic features have provided a basis for novel therapies in primary CAD. Infusions of rituximab, a chimeric human-murine anti-CD20 antibody known to be effective in B-cell lymphoma, produced partial response rates of approximately 50% and occasional complete responses. Median response duration, however, was only 11 months. Complement C3 and C4 depletion in many CAD patients, as well as Fc-gamma-RIIIa receptor polymorphism, have been proposed as explanations for the inconstant efficacy of rituximab therapy. In order to increase response rates and response duration, we are undertaking a phase 2 study of rituximab and fludarabine combination therapy. The preliminary results are encouraging, but further studies are required in order to allow firm conclusions.
Related Concept Videos
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:20Special Features of Adaptive Immunity
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
01:23Cells of the Adaptive Immune Response
01:36Humoral Immune Responses
01:40Cell-mediated Immune Responses
01:26Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...